Literature DB >> 28105663

Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy.

David D'Andrea1, Marco Moschini1,2, Kilian M Gust1,3, Mohammad Abufaraj1, Mehmet Özsoy1, Romain Mathieu4, Francesco Soria5, Alberto Briganti2, Morgan Rouprêt6, Pierre I Karakiewicz7, Shahrokh F Shariat1,3,8.   

Abstract

PURPOSE: To evaluate the role of lymphocyte-to-monocyte ratio (LMR) and neutrophil-to-lymphocyte ratio (NLR) as pre-operative markers for predicting extravesical disease and survival outcomes in patients undergoing radical cystectomy (RC) for urothelial carcinoma of the bladder (UCB).
MATERIALS AND METHODS: Data from 4335 patients undergoing RC for clinically non-metastatic UCB were analyzed. Multivariable logistic regression models were used to predict lymph node involvement and extravesical disease (defined as ≥pT3 and N0). Recurrence-free (RFS), cancer-specific (CSS), and overall survival (OS) were evaluated using multivariable Cox models. The accuracy of the models was assessed with receiver operating characteristics (ROC) curves and concordance-index.
RESULTS: Median LMR was 3.5 and median NLR was 2.7. Addition of LMR and NLR to a standard preoperative model improved its discrimination for prediction of lymph node metastasis by 4.5%. On multivariable analysis LMR and NLR independently predicted RFS, CSS, and OS. The discrimination of this model increased by adding LMR and NLR but was not significant.
CONCLUSIONS: LMR and NLR independently improved the preoperative prediction of lymph node metastasis and survival outcomes. As they are readily available, they could be integrated in a panel of preoperative markers helping selecting patients who have extravesical lymph node involvement and more aggressive disease.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  bladder; carcinoma; cystectomy; lymphocyte-to-monocyte ratio; neutrophil-to-lymphocyte ratio; transitional cell

Mesh:

Substances:

Year:  2017        PMID: 28105663     DOI: 10.1002/jso.24521

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  19 in total

1.  The prognostic role of preoperative circulating neutrophil-lymphocyte ratio in primary bladder cancer patients undergoing radical cystectomy: a meta-analysis.

Authors:  Guoming Hu; Feng Xu; Kefang Zhong; Shimin Wang; Qi Xu; Liming Huang; Pu Cheng
Journal:  World J Urol       Date:  2018-12-03       Impact factor: 4.226

2.  A panel of systemic inflammatory response biomarkers for outcome prediction in patients treated with radical cystectomy for urothelial carcinoma.

Authors:  Victor M Schuettfort; David D'Andrea; Fahad Quhal; Hadi Mostafaei; Ekaterina Laukhtina; Keiichiro Mori; Frederik König; Michael Rink; Mohammad Abufaraj; Pierre I Karakiewicz; Stefano Luzzago; Morgan Rouprêt; Dmitry Enikeev; Kristin Zimmermann; Marina Deuker; Marco Moschini; Reza Sari Motlagh; Nico C Grossmann; Satoshi Katayama; Benjamin Pradere; Shahrokh F Shariat
Journal:  BJU Int       Date:  2021-04-07       Impact factor: 5.969

Review 3.  Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature.

Authors:  Andrea Mari; Riccardo Campi; Riccardo Tellini; Giorgio Gandaglia; Simone Albisinni; Mohammad Abufaraj; Georgios Hatzichristodoulou; Francesco Montorsi; Roland van Velthoven; Marco Carini; Andrea Minervini; Shahrokh F Shariat
Journal:  World J Urol       Date:  2017-11-16       Impact factor: 4.226

4.  The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study.

Authors:  Jeenan Kaiser; Haocheng Li; Scott A North; Raya Leibowitz-Amit; Jo-An Seah; Nisha Morshed; Caroline Chau; Richard Lee-Ying; Daniel Y C Heng; Srikala Sridhar; Simon J Crabb; Nimira S Alimohamed
Journal:  Bladder Cancer       Date:  2018-04-26

5.  Evaluation of the clinical value of hematological parameters in patients with urothelial carcinoma of the bladder.

Authors:  Yuzhen Luo; Xiang Shi; Wenchao Li; Lijun Mo; Zheng Yang; Xiaohong Li; Liuqun Qin; Wuning Mo
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

6.  Prognostic Significance of the Lymphocyte-to-Monocyte Ratio in Bladder Cancer Undergoing Radical Cystectomy: A Meta-Analysis of 5638 Individuals.

Authors:  Jian-Ying Ma; Gang Hu; Qin Liu
Journal:  Dis Markers       Date:  2019-04-04       Impact factor: 3.434

7.  The evaluation of monocyte lymphocyte ratio as a preoperative predictor in urothelial malignancies: a pooled analysis based on comparative studies.

Authors:  Xuan Zhu; Shui-Qing Wu; Ran Xu; Yin-Huai Wang; Zhao-Hui Zhong; Lei Zhang; Xiao-Kun Zhao
Journal:  Sci Rep       Date:  2019-04-18       Impact factor: 4.379

8.  Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with urologic tumors: A PRISMA-compliant meta-analysis.

Authors:  Jialin Li; Yusheng Cheng; Zhigang Ji
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

9.  Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR.

Authors:  Takashi Kobayashi; Katsuhiro Ito; Takahiro Kojima; Satoru Maruyama; Shoichiro Mukai; Masakazu Tsutsumi; Jun Miki; Tomoya Okuno; Yuko Yoshio; Hiroaki Matsumoto; Toru Shimazui; Takehiko Segawa; Takashi Karashima; Kimihiko Masui; Fumimasa Fukuta; Kojiro Tashiro; Kazuto Imai; Shigetaka Suekane; Seiji Nagasawa; Shin Higashi; Tomohiro Fukui; Osamu Ogawa; Hiroshi Kitamura; Hiroyuki Nishiyama
Journal:  Cancer Immunol Immunother       Date:  2021-07-07       Impact factor: 6.968

10.  Meta-analysis of multiple hematological biomarkers as prognostic predictors of survival in bladder cancer.

Authors:  Lianghao Zhang; Longqing Li; Junxiao Liu; Jiange Wang; Yafeng Fan; Biao Dong; Zhaowei Zhu; Xuepei Zhang
Journal:  Medicine (Baltimore)       Date:  2020-07-24       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.